Latest kidney cancer news
A modified nivolumab/ipilimumab dosing regimen
In this phase 3b/4 study, people with advanced kidney cancer [...]
C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer
A biomarker is a biological molecule found in blood, other body [...]
Government’s new Health and Social Care Plan
Health and Social Care Secretary and Deputy Prime Minister, Thérèse [...]
Adjuvant pembrolizumab approved by NICE
Late last week we learnt that the National Institute for [...]
Telaglenastat plus cabozantinib in patients with metastatic kidney cancer
Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]
ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer
The phase 2 KEYNOTE-B61 study was presented at the recent [...]
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo kidney cancer sunitinib cabozantinib Sutent progression-free survival NHS England biomarkers ipilimumab pembrolizumab Cabometyx axitinib COVID-19 cancer survival non-clear cell kidney cancer VEGF inhibitors Inlyta coronavirus risk factors Yervoy adjuvant therapy Keytruda targeted therapy metastases papillary RCC everolimus biological markers ASCO Afinitor cancer outcomes first-line treatment NICEArchives
- 2025: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2024: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
